QuidelOrtho Corp
For the period ended Sep 27, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 27, 2026 · Filed Nov 4, 2026
QDEL$12.09+13.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
QuidelOrtho Corporation and its consolidated subsidiaries may be referred to as QuidelOrtho, the Company, we, our or us in this Quarterly Report, unless the context otherwise indicates. Throughout this Quarterly Report, we have used terms which are defined below:
| AOCI | Accumulated other comprehensive income (loss) |
|---|---|
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update |
| Board | Board of Directors |
| CEO | Chief Executive Officer |
| CFO | Chief Financial Officer |
| CODM | Chief Operating Decision Maker |
| Combinations | Business combination consummated by Quidel Corporation and Ortho on May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel Corporation, Ortho, QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc. |
| EBITDA | Earnings before interest, taxes, depreciation and amortization |
| EMEA | Europe, the Middle East and Africa |
| EPS | Loss per share |
| EU | European Union |
| Exchange Act | Securities Exchange Act of 1934, as amended |
| FASB | Financial Accounting Standards Board |
| GAAP | Generally accepted accounting principles in the U.S. |
| Grifols | Grifols Diagnostic Solutions, Inc. |
| IT | Information technology |
| IVD | In vitro diagnostics |
| Joint Business | Collaboration arrangement between Ortho and Grifols |
| JPAC | Japan and Asia Pacific |
| LEX Diagnostics | LEX Diagnostics Limited |
| OBBBA | One Big Beautiful Bill Act |
| OCI | Other comprehensive income (loss) |
| Optimization Plan | Multi-year, enterprise-wide cost-reduction, strategic productivity and margin improvement initiatives that the Company launched in the second quarter of 2025 |
| Ortho | Ortho Clinical Diagnostics Holdings plc |
| Prior Credit Agreement | Credit agreement, dated May 27, 2022, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and L/C issuers party thereto |
| Quarterly Report | Quarterly Report on Form 10-Q for the quarter ended September 27, 2026 |
| R&D | Research and development |
| RSU | Restricted stock unit; includes time-based RSUs, performance-based RSUs and restricted stock awards |
| RSV | Respiratory syncytial virus |
| SAVANNA Exit | Discontinuation of the development of the SAVANNA platform |
| SEC | Securities and Exchange Commission |
| Securities Act | Securities Act of 1933, as amended |
| SOFR | Secured overnight financing rate |
| Term Loans | Collectively under the Credit Agreement: (i) a $1.15 billion Term Loan A, (ii) a $100.0 million DDTL Term Loan A, and (iii) a $1.45 billion Term Loan B |
| U.K. | United Kingdom |
| U.S. | United States |
| USD | United States dollar |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.